Crohn’s disease is an inflammatory bowel disease that causes abdominal pain and severe diarrhea. This condition is not curable, more than 50% of patients have benefitted from the ozanimod treatment. The objective of this study is to examine the efficacy of ozanimod induction therapy in patients with moderate to severe Crohn’s disease.
This is an uncontrolled, multicenter trial study that included 69 patients diagnosed with moderate to severely active Crohn’s disease. The patients were initially given a seven-day dose escalation of ozanimod (0.25 mg for 4 days and 0.5 mg for 3 days), followed by a 1 mg daily dosage for the next 11 weeks. The main outcome was a change in the Simple Endoscopic Score for Crohn’s Disease (SES-CD) from week 1 to week 12.
The mean change in SES-CD after 12 weeks was -2.2. Besides, the researchers also observed a significant reduction of Crohn’s Disease Activity Index, Geboes Histology Activity Score, and Robart’s Histopathology Index. Adverse events were reported in 18 (26%) patients, with the most common adverse events being returning Crohn’s disease and abdominal abscess.
The research concluded that a 12-week ozanimod therapy resulted in significant histological, endoscopic, and clinical improvements in patients with moderate to severely active Crohn’s disease.